title: Efficacy with high-dose aripiprazole after olanzapine-related metabolic disturbances.
abstract: OBJECTIVE
  To report a case in which a patient tolerated and responded to high-dose aripiprazole and lost weight after having been on olanzapine for several years; a secondary objective is to discuss the use of aripiprazole dosages at higher than those recommended in the product's labeling.
  
  
  METHODS
  A 57-year-old man with a 30 year history of schizophrenia had been taking olanzapine for 4 years, with the dosage titrated to 20 mg/day, to control the psychosis. After he had gained significant weight with olanzapine (the highest was 102.7 kg), his treatment was switched to aripiprazole. The patient required a high dose of aripiprazole (60 mg/day) to achieve full control of the psychiatric symptoms, and during aripiprazole therapy, he lost the weight he had gained while on olanzapine, weighing 85.9 kg within 7 months after the therapy switch.
  
  
  CONCLUSIONS
  Dosages of atypical antipsychotics higher than those recommended by the Food and Drug Administration are often used in clinical practice for refractory patients, despite the lack of evidence. The literature available on this subject is limited to small, double-blind trials; open-label trials; and case reports. Although certain patients may benefit from higher doses of atypical antipsychotics, the lack of evidence limits their use.
  
  
  CONCLUSIONS
  High-dose aripiprazole (60 mg/day) was well tolerated and controlled this patient's symptoms effectively. In addition, he lost weight that was gained while being treated with olanzapine. High-dose aripiprazole may be beneficial and safe in refractory patients; however, large, double-blind, randomized clinical trials are needed.
authors.affiliation: Ernest Mario College of Pharmacy, Rutgers, State University of University of New Jersey, Sea Bright 07760-2210, USA. ufrxchavez@aol.com
authors.forename: Benjamin
authors.initials: B
authors.lastname: Chavez
authors.forename: Rene A
authors.initials: RA
authors.lastname: Poveda
mesh_terms: D014150:Antipsychotic Agents / Q000008:administration & dosage*; D000068180:Aripiprazole; D001569:Benzodiazepines / Q000009:adverse effects / Q000494:pharmacology; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D008297:Male; D008659:Metabolic Diseases / Q000097:blood / Q000139:chemically induced; D000077152:Olanzapine; D010879:Piperazines / Q000008:administration & dosage*; D015363:Quinolones / Q000008:administration & dosage*; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy; D015430:Weight Gain / Q000187:drug effects* / Q000502:physiology
chemical_list: D014150:Antipsychotic Agents; D001786:Blood Glucose; D010879:Piperazines; D015363:Quinolones; D001569:Benzodiazepines; D000068180:Aripiprazole; D000077152:Olanzapine